Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Smith, IE
  • Biganzoli, L
  • Cortes-Funes, H
  • Stroyakovskiy, D
  • Franke, FA
  • Chlistalla, A
  • Pierga, J-Y
  • Thomssen, C
  • Pritchard, Kathleen

publication date

  • January 15, 2009